cyrilzakka/clinical-trials huggingface dataset:
The Effect of Low-Level Laser Therapy in Carpal Tunnel Syndrome

Carpal tunnel syndrome (CTS) is a chronic compression of the median nerve, which can lead to symptoms such as nocturnal pain and paresthesia in the area innervated by the median nerve. The affected patients also describe discomfort and hypoesthesia in the nerve supply area. Due to the COVID (Coronavirus disease) pandemic, CTS operations have been postponed and delayed. A promising and safe alternative for improving CTS-related symptoms appears to be non-invasive, non-thermal low-level-laser therapy. As a possible conservative, alternative method, low-level-laser therapy has the potential to enable patients with CTS to improve their disease-related symptoms or at least to alleviate the symptoms until the indicated CTS operation (carpal tunnel release).

The aim of this randomized, single-blind, placebo-controlled clinical trial is to investigate the influence of 3 weeks of low-level-laser therapy on the symptoms typical of CTS in patients with surgery-indicated carpal tunnel syndrome and its influence on quality of life.


Eligibility Criteria:
Inclusion Criteria:

* Existing written consent of the participating person after informed consent.
* The patient is capable of giving consent.
* Isolated surgery-induced CTS
* CTS patients with pain (NRS between 2 and 6) and/or paresthesia and/or nocturnal pain that has been present for at least 3 months (pain reported using the "Numerical Rating Scale for Pain" (NRS) between 0 and 10).
* Compliance with 3 weeks of cold light therapy.

Exclusion Criteria:

* Absence of informed consent
* Patients under 18 years or over 80 years
* Patients from protected groups as well as people who are not able to personally give consent
* Participation in other clinical trials within the last 4 weeks before the start of the study
* traumatic and atraumatic median nerve lesions/damage/narrowing
* Previous operations in the area innervated by the median nerve or in the area of the affected upper extremity/hand
* CTS recurrence of the affected hand
* Thenar atrophy of the affected hand
* Nerve diseases that affect the upper extremity including the hand (e.g. polyneuropathy)
* Cervical radiculopathy C6/C
* Osteoarthritis of the affected hand (e.g. rhizarthrosis)
* Arthritis of the affected hand
* Metabolic diseases that have an influence on the sensory or function of the hand
* Vascular diseases affecting the upper extremity or hand (e.g. Raynaud's syndrome)
* other compressions or injuries of the median nerve (e.g. thoracic outlet syndrome, scalene syndrome, pronator teres syndrome)
Proton RT for the Treatment of Pediatric Rhabdomyosarcoma

The main purpose of this study is to see if using proton beam radiation therapy instead of photon beam radiation therapy can reduce side effects from radiation treatment for rhabdomyosarcoma. Photon beam radiation is the standard type of radiation for treating most rhabdomyosarcoma and many other types of cancer. Photon beam radiation enters the body and passes through healthy tissue, encounters the tumor, then leaves the body through healthy tissue. A beam of proton radiation enters the body and passes through healthy tissue, encounters tumor, but then stops. This means that less healthy tissue is affected by proton beam radiation than by photon beam radiation.

* A special device is made for each participant to help them hold still during the treatment. This may be in the form of a mask or a custom made foam cradle depending on the area to be treated.
* Radiation treatments will be given once per day, 5 days a week for a total of 4 to 6 weeks, depending upon how much total dose the tumor requires.
* Participants will be seen once per week by their radiation doctor to monitor health and record any side effects from treatment.
* After the radiation treatments are completed, participants will be required to undergo further tests and evaluations for several years following treatment.

Eligibility Criteria:
Inclusion Criteria:

* Patients with biopsy proven newly diagnosed rhabdomyosarcoma.
* Patients less than or equal to 21 years of age.
* Patients must be treated with a standardly accepted chemotherapy regimen.
* May not have metastatic disease unless aged 2-10 with embryonal histology.
* Must be willing to receive follow-up care for a minimum of five years after treatment at MGH and annual visits unless it is too difficult to return to MGH for follow-up care. In that event, they must be willing to have their outside medical information released to us to track the results.
* Timing of radiation must be according to the IRB protocol upon which the patient is treated within either 35 days of last chemotherapy or surgery.

Exclusion Criteria:

* Life expectancy of less than 2 years.
* Co-morbidities that would make the use of radiation too toxic to deliver safely, such as serious local injury or collagen vascular disease.
* Patients who are pregnant
* Previous treatment with radiation therapy.
Creation of a Bank of Fibroblast From Patients With Amyotrophic Lateral Sclerosis: Pilot Study

Patients with ALS will be included in the reference center for ALS in hospital La Pitié Salpêtrière, Paris.

The study proposes to investigate the pathophysiology of ALS by setting up a fibroblast bank for studying molecular, cellular and genetic parameters of the pathology.

iPS (induced pluripotent stem cells) and then differentiated cells will be generated.

The pathophysiology of ALS will be studied on the 3 types of cells (fibroblasts, iPS, differentiated cells).


Eligibility Criteria:
Inclusion Criteria:

* patients over 18 years old
* ALS sporadic or familial or unknown

Exclusion Criteria:

* known cutaneous disease not allowing the biopsy
* platelets less than 10 000/m3
* suspected or known xylocain allergy
Impact of Ostom-i Alert Sensor on Quality of Life in Patients With Ileostomy

The purpose of this study is to evaluate patient satisfaction and quality of life in patients with ileostomy managed with or without the novel Ostom-i Alert device.

Patients with ileostomy have impaired quality of life related to their ileostomy (Person et al. DCR. 2012; 55: 783 - 787; Scarpa et al. Colorectal Dis. 2010; 12: 914 - 920). Although patients with ileostomy have better overall quality of life compared with colostomy patients (Silva et al. Worl J Surg. 2003; 27: 421-424), the liquid nature of the ileostomy effluent predisposes these patients to bag overfilling and dehydration more so than colostomy patients (Paquette et al. DCR 2013; 56: 974-979). This may be specifically important in populations with long term or permanent ileostomy. Overfilling and breakage/leakage of the ileostomy bag can also affect patient's ability to function in social environments, go out in public, have intimate relationships with significant others, and interfere with sleep patterns (due to high output and nighttime overfilling of the ileostomy bag).

The Ostom-i Alert is a novel device developed by a patient with ileostomy and now FDA approved in the United States. The device is a sensor that clips onto any ostomy bag and sends a Bluetooth signal to a mobile device app. An alarm lets the patient know before the stoma bag is at risk for overfilling and leaking. The potential advantage is that the device can prevent unexpected bag overfilling, breakage, and nighttime accidents. This may therefore lead to improved quality of life. The volume and output recordings can also be stored and emailed to the patient's health care providers, with potential to reduce ostomy related dehydration through more accurate volume recording and sharing.

While the device has many applications, the purpose of this research study is to specifically evaluate patient quality of life after application of the Ostom-i Alert compared with standard ostomy care.

Eligibility Criteria:
Inclusion Criteria:

1. Patients with ileostomies in place without a plan for ileostomy take down in the next 4 months.
2. Able to freely give written informed consent to participate in the study and have signed the Informed Consent Form;
3. Males or females, age 18 and older at the time of study screening;
4. Patients with loop or end ileostomy at least 1 month since ileostomy creation
5. No plan for stoma reversal for the next 4 months to allow adequate time for study inclusion
6. Patients who own an iPhone, iPod Touch, or Android device

Exclusion Criteria:

1. Mentally incompetent or unable or unwilling to provide informed consent or comply with study procedures;
2. Children \<18
3. Pregnant patients
4. Patients with planned ileostomy closure in the next 4 months
5. Patients with colostomy, more than one ostomy, or urostomy
6. Patients unable or unwilling to come in for in person Ostomi-I Alert teaching and screening visits
7. Patients without an iPhone, iPod Touch, or Android device
Nomograms to Precisely Predict Conditional Risk of Survival for Patients With Laryngeal Cancer

Advanced laryngeal squamous cell carcinoma (SCC) remains a highly morbid and fatal disease despite aggressive interventions. Mortality is high in this cohort: laryngeal cancer affects over 13 000 patients in the United States, with over 3500 deaths annually.The results of the Veterans Affairs Cooperative Studies Program Laryngeal Cancer Trial and subsequent studies demonstrated similar overall survival (OS) rates for organ preservation protocols involving radiotherapy (RT) or chemoradiotherapy (CRT) when compared to surgery, with the benefit of preserving the larynx in a large majority of patients. As such, the use of RT or CRT has become the predominant initial intervention for patients with laryngeal SCC.However, the prognosis of recurrent and persistent laryngeal SCC is particularly dire.In this study,the investigators sought to identify preoperative predictors of survival for patients with recurrent or persistent laryngeal SCC in order to set patient expectations and address modifiable risk factors. Identification of predictors of survival may also identify patients who could benefit from novel therapeutic agents in a neo/adjuvant fashion. Herein,we examine a cohort of patients with recurrent or persistent laryngeal SCC after definitive RT/CRT who has undergone total laryngectomy in order to identify potential preoperative predictors of clinical outcomes.

Demographic, clinical, and survival data were abstracted. Death was verified via medical records and the social security death index. Primary outcome measures were OS (time from salvage laryngectomy to death from any cause), disease-specific survival (DSS; time from salvage laryngectomy to death from recurrent/persistent laryngeal SCC), and DFS (time from salvage laryngectomy to laryngeal SCC recurrence)

Eligibility Criteria:
Inclusion Criteria:

* laryngeal carcinoma patients with radical surgery

Exclusion Criteria:

* multiple primarry malignant neo-plasms
Assessment of Diagnostic and Therapeutic Practices for Cardiac Implantable Electronic Devices Suspected Infections in Nancy University Hospital

The frequency of cardiac implantable electronic devices (CIED) is constantly increasing.

Devices infections are one of the most serious complications in terms of morbidity and mortality. Although the frequency of cardiac implantable devices infections is difficult to derminate due to divergent definitions, cohort studies report a trend of increasing.

The infection can be localized at the pocket of the implantation, at intravascular or intra-cardiac portion of leads. Infectious endocarditis defined by involvement of the intra-cardiac portion of leads is the most serious form. The diagnosis is based on clinical, biological and multimodal imagery data. Early diagnosis and specific management are necessary to reduce mortality and morbidity.

Since the last European recommendations on infectious endocarditis in 2015, the HeartRythm Society of patient described an algorithm to treat CIED infections and extraction indications.

However, in practice, management of CEID infections remains center-dependent and data from robust international studies are missing.

The main objective of our study is to evaluate the management of CEID suspected infections and the prognosis at 1 year in terms of survival according to the methods of treatment at the Nancy University Hospital and to compare the treatment with the latest recommendations in force


Eligibility Criteria:
Inclusion Criteria:

* All patients who have been hospitalized in Nancy University Hospital between January 2014 et July 2019 for suspected infection of cardiac implantable electronic device

Exclusion Criteria:

* Minor patients
* Epicardial CIED
Multi-modal Imaging and Artificial Intelligence Diagnostic System for Multi-level Clinical Application

This study is to build an multi-modal artificial intelligence ophthalmological imaging diagnostic system covering multi-level medical institutions. We are going to evaluate this system in an evidence-based medicine view, taking diabetic retinopathy as an example. And clinical diagnostic criteria will be made based on this multi-modal artificial intelligence imaging diagnostic system. The study is designed as a cross-sectional study involving 1,000 normal individuals, 1,000 diabetes patients without ocular complications, and 1,000 with diabetic ocular complications. Statistical analysis of the diagnostic sensitivity and specificity of the artificial intelligence system will be made, and ROC curve wil be draw.


Eligibility Criteria:
Inclusion Criteria:

Group A(normal individuals): Meet all the items 1 \~ 5 below

1. No familial or hereditary retinopathy;
2. No history of ocular trauma and / or history of ocular disease (except for mild to moderate refractive errors and / or age-related cataracts);
3. No drug use history that may cause side effects of retina (such as chloroquine, hydroxychloroquine, chlorpromazine, rifampin, etc.); 4 binocular diopter ≤ ± 6.00D; No systemic diseases that may affect the retina.

Group B(diabetes patients without ocular complications): meet any of 1 to 3, and both 4 to 5 items

1. Diagnosed with type 1 diabetes for more than 5 years;
2. Diagnosed with type 2 diabetes patients;
3. Diagnosis of gestational diabetes patients;
4. Without systemic disease that may affect the retina except for diabetes;
5. Meet the standards of 1 to 4 items.

Group C(patients with diabetic ocular complications): meet with any of 1 to 3, and all 4 to 6 items

1. Diagnosed with type 1 diabetes for more than 5 years;
2. Diagnosed with type 2 diabetes patients;
3. Diagnosis of gestational diabetes patients;
4. Meet the guidelines for diagnosis and treatment of diabetic retinopathy in any stage of diabetic retinopathy and / or diabetic macular edema.
5. Without systemic disease that may affect the retina except for diabetes;
6. A group to meet the criteria for 1 to 4 items.

Exclusion Criteria:

1. Refractive pathway is turbid, so that fundus image can not be clearly photographed;
2. With other fundus diseases and / or other diseases that seriously affect the visual function;
3. Any eye infection, such as conjunctivitis, keratitis, scleritis, endophthalmitis, acute and chronic dacryocystitis, or eye injury;
4. Serious systemic diseases such as diabetes, hypertension, heart failur,renal failure;
5. Can not cooperate with the examiner due to mental or other reasons.
Vaginal Postpartum Pain Management Protocol Comparison

Untreated postpartum pain has been associated with increased risk of opioid use, postpartum depression and development of persistent pain. In this study the investigators will investigate whether a scheduled administration of analgesics is superior to administration of analgesics based on patient request following a vaginal delivery.

More than two million women deliver vaginally every year in the United States (US). Along with the joy and happiness of having a new member in the family, women may suffer from cramping pain and lower abdomen discomfort following uterine involution; perineal pain due to perineal trauma or episiotomy; and nipple pain from breastfeeding or breast engorgement.

A stepwise approach using multimodal combination of medications can effectively provide an individualized pain management for women in their postpartum period. The first step includes non-opioid analgesics (as paracetamol and NSAIDs), step two adds milder opioids (as codeine, tramadol and oral morphine), and step three incorporates stronger opioids (as parenteral morphine).

In this study the investigators will investigate whether a scheduled administration of analgesics is superior to administration of analgesics based on patient request following a vaginal delivery.

Eligibility Criteria:
Inclusion Criteria:

1. Women following term vaginal delivery.

Exclusion Criteria:

1. Under Age 18 years or older than 45 years.
2. Women with chronic pain syndrome.
3. Women with relative or absolute contraindications for paracetamol or NSAIDs.
Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities

The purpose of study was to test whether rivaroxaban added to standard of care treatment, when compared to placebo, had the potential to reduce the incidence of the clinical events related to the clots and complications of the heart and brain (CV death, MI, or stroke) or the legs (acute limb ischemia or major amputation) in patients who had undergone recent procedure(s) to improve the blood flow of their legs.


Eligibility Criteria:
Inclusion Criteria:

* Age ≥50
* Documented moderate to severe symptomatic lower extremity atherosclerotic peripheral artery disease
* Technically successful peripheral revascularization distal to the external iliac artery for symptomatic PAD (Peripheral artery disease) within the last 10 days prior to randomization

Exclusion Criteria:

* Patients undergoing revascularization for asymptomatic PAD or mild claudication without functional limitation of the index leg.
* Patients undergoing revascularization of the index leg to treat an asymptomatic or minimally symptomatic restenosis of a bypass graft or target lesion restenosis.
* Prior revascularization on the index leg within 10 days of the qualifying revascularization.
* Planned dual antiplatelet therapy (DAPT) use for the qualifying revascularization procedure of clopidogrel in addition to Acetylic salicylic acid (ASA) for \>6 months after the qualifying revascularization procedure; it is strongly recommended that any course of clopidogrel is kept to the minimum necessary in accordance with local standard of care and international practice guidelines (typically 30 days, or up to 60 days for some drug-coated products or devices) and is only allowed for up to 6 months for complex procedures or devices in the investigator's opinion that require longer use.
* Planned use of any additional antiplatelet agent other than clopidogrel and ASA after the qualifying revascularization procedure.
Thenar Muscle Ultrasound in CTS Evaluation

This study will include 20 patients aged 18-75 years who have been diagnosed with carpal tunnel syndrome (CTS) based on electrophysiological examinations performed within the last three months, as well as 20 healthy volunteers without a CTS diagnosis. Sociodemographic data such as age, gender, height, weight, and BMI will be recorded. Pinch grip strength will be evaluated using a Jamar pinch meter, and hand grip strength will be assessed using a Jamar dynamometer. Ultrasound will be used to measure the cross-sectional area and thickness of the thenar muscles as well as the cross-sectional area of the median nerve. Additionally, previous electrophysiological examination results will be recorded for the CTS patients.


Eligibility Criteria:
Inclusion Criteria:

* Patients aged 18-75 years.
* Diagnosed with carpal tunnel syndrome based on electrophysiological examination within the last 3 months.
* Healthy volunteers without a diagnosis of carpal tunnel syndrome.
* Volunteered to participate in the study.

Exclusion Criteria:

* Refusal to participate in the study.
* History of surgery due to carpal tunnel syndrome.
* Presence of neuromuscular diseases.
* Presence of advanced osteoarthritis.
* Presence of psychiatric disorders.
* Presence of cognitive impairments that may hinder study participation.
Telemedicine in Sleep Breathing Disorders: a Multicenter Study.

In recent years medicine has been enhanced by the incorporation of technological innovations from areas as diverse as cell biology, biochemistry, genetics, biophysics and bioengineering. One of the few exceptions in this rapid process of implementing technological advances occurs in clinical medicine, where its penetration is much less effective than in other scientific and professional fields, or even in everyday life. Attempts to tackle this problem have given rise to various initiatives in the US and Europe, including Spain.

There is a surprising paucity of telemedicine systems in clinical practice, especially with respect to sleep-related breathing disorders, and most particularly obstructive sleep apnea (OSA), where protocols are urgently needed to alleviate this healthcare problem represented by its under-diagnosis and comorbidity, as well as the long waiting lists for treatment. In others words, the growing awareness of sleep disorders, especially OSA, has not been accompanied by strategic changes in the cost-effective diagnosis and/or treatment of these diseases.

CPAP therapy compliance is not always appropriate. Helping patients during the first two months usually determines compliance. Therefore, the development of strategies to support the patient during the first weeks is essential. However, this "collides" with reality, where it is difficult to properly care all patients because of congested sleep units. It is therefore necessary to implement new and imaginative control schemes especially at the beginning of the treatment. Patients' follow-up performed by telemedicine technology is an option that aims to substitute the face-to-face visits or at least reduce them considerably. In a future context, the idea is that the professional in charge of CPAP patients monitoring has on his/her agenda face-to-face visits and televisits (at distance) and information which patient will provide through online questionnaires with a certain frequency.

In this sense, this project aims to analyze whether CPAP treatment compliance of OSA patients monitored by telemedicine techniques (website and televisits) is similar to that achieved by standard monitoring but more cost-effective. The study design is a multicenter randomized trial with parallel groups and blind final evaluation after CPAP treatment following two different strategies: one through conventional monitoring in the hospital (face-to-face visiting) and another by telemedicine monitoring (non-contact visiting and website).


Eligibility Criteria:
Inclusion Criteria:

* diagnosis of OSA;
* 18-75 years;
* CPAP recommendation;
* Informed consent.

Exclusion Criteria:

* Disabling hypersomnia;
* Pregnancy;
* Psychiatric disorders;
* Previous treatment with CPAP;
* Clinical instability in the previous month;
* Inability to use information technologies (computers and web).